After recent troubles, Catalent expands its biologics services platform

June 12, 2023  Source: drugdu 97

"/
Global CDMO giant Catalent, which has been struggling through difficult financial times, added more biologic processes to its OneBio platform, which features capabilities for antibody and recombinant proteins, cell and gene therapies, and messenger RNA.The rollout of the added services is part of the company’s participation at the BIO International Convention taking place in Boston this week, Catalent said in a June 5 press release.
The additions come in the wake of the CDMO delaying the release of its earnings report multiple times after admitting in April that it was struggling with “productivity issues” and high costs at three major production sites—including two of its largest.
The locations at issue include Catalent’s gene therapy manufacturing site in Harmans, Maryland, as well as its drug product and drug substance plants in Bloomington, Indiana, and Brussels, Belgium.
Catalent’s problems may have caused life sciences conglomerate Danaher to shelve plans in April to acquire the CDMO for a premium price. Still, reports have circulated that Danaher could revive a takeover offer.
Catalent’s OneBio platform, which debuted in 2019, provides accelerated programs from development to manufacturing that include fill/finish and packaging and support for clinical supply and commercial launch. With the latest additions, the service reaches across biologic modalities and service offerings.
“We have been able to demonstrate how beneficial the OneBio integrated biologics development solution can be to sponsors, saving them time on managing multiple partners and handoffs between companies,” Karen Flynn, Catalent’s interim president and head of its bio modalities unit, said in the release.
Catalent has been busy the past few years building up its cell and gene therapy services.
In 2020, the company snapped up Belgian CDMO MaSTherCell Global for $315 million. As part of that deal, Catalent got a contract producer with cell and gene therapy expertise.

Reference: https://www.fiercepharma.com/manufacturing/catalent-tacks-more-biologic-services-its-onebio-platform

By editor
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.